PCSK9 inhibition produces incremental benefits on coronary disease progression in patients treated with statins.
Researchers observed significant improvement in LDL cholesterol in those at risk for diabetes.
Statin-based therapy had a smaller effect in reducing major vascular events in patients with advanced chronic kidney disease.
Researchers found that dietary changes, other medications, and surgery can also lower cardiovascular risk.
Current evidence is insufficient to weigh the balance of benefits and harms of screening.
To combat the stigma associated with selective screening, the American Academy of Pediatrics has called for all children to be screened for high cholesterol, depression, and HIV.
A CDC team analyzed national data from 2005 through 2014 and discovered that 35% of Americans eligible to take cholesterol-lowering medication were not taking the drugs.
The drug is approved for patients who are unable to control their LDL cholesterol with current treatment options.
The 2013 ACC/AHA cholesterol management guidelines better identify the risk of CVD and presence of coronary artery disease.
The FDA approved Praluent (alirocumab), the first injectable PCSK9 inhibitor for high cholesterol.
Adiposity and lipid outcomes improved in 15% of obesity prevention programs aimed at children.
Lipoprotein improvements from fenofibrate greater for women than men; CVD event reduction similar.
More than 40% of those taking high-dose statins don't reach LDL-C target of <70 mg/dL
Agencies should consider re-evaluating the recommendation that patients fast before obtaining a lipid panel.
Adverse effects have been found in 34.2% and 32.5% of patients prescribed extended-release niacin.
The longest time to achieve pregnancy occurred in couples in which both partners had high cholesterol levels.
Research suggests that lowering LDL has a non-significant impact on end-stage renal disease.
Company issues recall due to defects in product packaging
New cholesterol risk calculator may overestimate heart disease risk.
Four major statin benefit groups identified for whom benefits outweigh risk of adverse events.
Drug manufacturer recalls 41 lots of atorvastatin calcium tablets due to potential contamination with small glass particles.
Few statistically significant differences in cholesterol subclass levels were observed among patients who fasted for various lengths of time.
As LDL goals become more aggressive, therapeutic lifestyle changes are increasingly important in achieving recommended lipid levels.
Cholesterol levels and related lipids among U.S. adults have dropped steadily from 1988 to 2010.
Using plumbing as an analogy for atherosclerosis can help improve treatment adherence.
Increased weight-to-height ratio was associated with worse lipid profiles and hypertension in adolescents.
Drug interactions between statins and certain protease inhibitors for HIV or hepatitis C can increase the risk for myopathy, including rhabdomyolysis.
Positive change in fitness or fatness can reduce the risk for cholesterol, hypertension and metabolic syndrome.